ARCHIVES

Did Iressa Data Merit Approval? Experts Discuss Implications For Drug Development, Lung Cancer Treatment, Reimbursement (12-page issue).

This article is from The Cancer Letter archive.

Vol. 29 No. 19 | May 9, 2003

Download PDF Visit The Full Archive

Related Articles

Statistical Models Determine Stem-Cell Transplant Effectiveness

July 26, 2013

Working Group: Restructure NCI, Improve Review Process, Encourage Independence

July 14, 1995

New Abiraterone Acetate Results Show Greater Benefit Than Before

June 24, 2011

Alan Rabson Named Acting NCI Director

October 5, 2001

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

December 16, 2005

Geography Still An Issue For Centers: Durant Asks Is It “Holy Water” or Money

April 26, 1985